Fentanyl Citrate Injection Shortage: Current Availability and Manufacturer Updates

What’s in Shortage

Fentanyl Citrate Injection (Brand Name: FENTANYL CITRATE) is currently listed in a shortage status by the FDA. This medication is categorized for use in Analgesia/Addiction and Pediatric care. The shortage involves specific presentations of the injection dosage form.

Which Manufacturers Are Affected

Fresenius Kabi USA, LLC is the primary manufacturer listed for this shortage. The availability varies by specific product presentation:

• Unavailable: Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11). The manufacturer notes the next release is expected in February 2026.
• Unavailable: Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05). The manufacturer notes the next release is expected in February 2026.
• Available: Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20, 63323-806-01, 63323-806-02, 63323-806-50).

For all presentations, the manufacturer advises checking with wholesalers for current inventory.

Manufacturer Contact Information:

• Fresenius Kabi USA, LLC: 888-386-1300

Why There’s a Shortage

The reason for the shortage is officially listed as “Other.” No further specific details regarding production delays or supply chain issues were provided in the database.

What Patients Should Do

If you or a family member are prescribed Fentanyl Citrate Injection, please consider the following steps:

• Consult Your Healthcare Provider: Patients should always consult with their doctor or healthcare provider regarding their treatment plan and any potential impact this shortage may have on their care.
• Speak with Your Pharmacist: Pharmacists often have the most up-to-date information on local inventory and can check with various wholesalers.
• Contact the Manufacturer: You may use the contact information provided above to inquire about supply timelines for specific NDCs.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult their healthcare provider for all medical decisions and alternative treatment options.

Source

This information is based on the FDA Drug Shortage Database. Initial Posting Date: 01/01/2012
Last Updated: 02/05/2026